Tags

Type your tag names separated by a space and hit enter

Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study.
Reprod Sci. 2014 Dec; 21(12):1518-25.RS

Abstract

This Phase III, uncontrolled, open-label, multicenter study was conducted to investigate the contraceptive efficacy, bleeding pattern, and cycle control of a novel once-a-week contraceptive patch, delivering low-dose ethinyl estradiol (EE) and gestodene (GSD) at the same systemic exposure seen after oral administration of a combined oral contraceptive containing 0.02 mg EE/0.06 mg GSD. Participants were women aged 18 to 35 years, all of whom received the EE/GSD patch for 13 cycles each of 21 treatment days (one patch per week for 3 weeks) followed by a 7-day, patch-free interval. The primary efficacy variable was the occurrence of unintended pregnancies during the study period as assessed by life table analysis and the Pearl Index. Secondary efficacy variables were days with bleeding during four 90-day reference periods and during 1 treatment year, bleeding pattern, and cycle control. The Kaplan-Meier probability of contraceptive protection after 364 treatment days was 98.8% and the adjusted Pearl Index was 0.81. The percentage of participants with intracyclic bleeding/spotting decreased over time, from 11.4% to 6.8% in cycles 1 and 12, respectively. Almost all participants (range: 90.8%-97.6%) experienced withdrawal bleeding across the study period. Compliance was very high (mean: 97.9%; median: 100%). The most frequent adverse events were headache (9.5%) and application site reaction (8.5%); no clinically significant safety concerns were observed. Results suggest the EE/GSD patch is highly effective in preventing pregnancy. Menstrual bleeding pattern was favorable and within the ranges expected of a healthy female population. The patch was well tolerated and treatment compliance was high.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, MVZ Kinderwunschzentrum Wiesbaden GmbH, Wiesbaden, Germany Faculty of Medicine of the Johann Wolfgang Goethe-University Frankfurt/Main, Germany.Department of Reproductive Biology, Biomedical Research Centre, University of Coahuila, Coahuila, Mexico.Sydney Centre for Reproductive Health Research, FPNSW and University of Sydney, Sydney, Australia.Women's Health, Bayer Pharma AG, Berlin, Germany.Women's Health, Bayer Pharma AG, Berlin, Germany martin.merz@bayer.com.

Pub Type(s)

Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24784719

Citation

Wiegratz, Inka, et al. "Effect of a Low-dose Contraceptive Patch On Efficacy, Bleeding Pattern, and Safety: a 1-year, Multicenter, Open-label, Uncontrolled Study." Reproductive Sciences (Thousand Oaks, Calif.), vol. 21, no. 12, 2014, pp. 1518-25.
Wiegratz I, Bassol S, Weisberg E, et al. Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study. Reprod Sci. 2014;21(12):1518-25.
Wiegratz, I., Bassol, S., Weisberg, E., Mellinger, U., & Merz, M. (2014). Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study. Reproductive Sciences (Thousand Oaks, Calif.), 21(12), 1518-25. https://doi.org/10.1177/1933719114532840
Wiegratz I, et al. Effect of a Low-dose Contraceptive Patch On Efficacy, Bleeding Pattern, and Safety: a 1-year, Multicenter, Open-label, Uncontrolled Study. Reprod Sci. 2014;21(12):1518-25. PubMed PMID: 24784719.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study. AU - Wiegratz,Inka, AU - Bassol,Susana, AU - Weisberg,Edith, AU - Mellinger,Uwe, AU - Merz,Martin, Y1 - 2014/04/30/ PY - 2014/5/3/entrez PY - 2014/5/3/pubmed PY - 2015/8/15/medline KW - ethinyl estradiol KW - female contraception KW - gestodene KW - pearl index KW - transdermal SP - 1518 EP - 25 JF - Reproductive sciences (Thousand Oaks, Calif.) JO - Reprod Sci VL - 21 IS - 12 N2 - This Phase III, uncontrolled, open-label, multicenter study was conducted to investigate the contraceptive efficacy, bleeding pattern, and cycle control of a novel once-a-week contraceptive patch, delivering low-dose ethinyl estradiol (EE) and gestodene (GSD) at the same systemic exposure seen after oral administration of a combined oral contraceptive containing 0.02 mg EE/0.06 mg GSD. Participants were women aged 18 to 35 years, all of whom received the EE/GSD patch for 13 cycles each of 21 treatment days (one patch per week for 3 weeks) followed by a 7-day, patch-free interval. The primary efficacy variable was the occurrence of unintended pregnancies during the study period as assessed by life table analysis and the Pearl Index. Secondary efficacy variables were days with bleeding during four 90-day reference periods and during 1 treatment year, bleeding pattern, and cycle control. The Kaplan-Meier probability of contraceptive protection after 364 treatment days was 98.8% and the adjusted Pearl Index was 0.81. The percentage of participants with intracyclic bleeding/spotting decreased over time, from 11.4% to 6.8% in cycles 1 and 12, respectively. Almost all participants (range: 90.8%-97.6%) experienced withdrawal bleeding across the study period. Compliance was very high (mean: 97.9%; median: 100%). The most frequent adverse events were headache (9.5%) and application site reaction (8.5%); no clinically significant safety concerns were observed. Results suggest the EE/GSD patch is highly effective in preventing pregnancy. Menstrual bleeding pattern was favorable and within the ranges expected of a healthy female population. The patch was well tolerated and treatment compliance was high. SN - 1933-7205 UR - https://www.unboundmedicine.com/medline/citation/24784719/Effect_of_a_low_dose_contraceptive_patch_on_efficacy_bleeding_pattern_and_safety:_a_1_year_multicenter_open_label_uncontrolled_study_ L2 - http://journals.sagepub.com/doi/full/10.1177/1933719114532840?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -